Eurazeo: first closing for Biofund IV

(CercleFinance.com) - Eurazeo has announced that Kurma Partners, its management company specialising in improving human health, has achieved a first closing of E140m for its new Biofund IV biotech fund, with a final target of E250m by 2025.


The fundraising benefits from the track-record of Biofund III investments, which achieved several landmark exits, Eurazeo says, adding that Biofund IV is targeting 16 to 20 new investments by pursuing the strategy that has made Kurma so successful.

To date, Biofund IV has already made three investments in SciRhom, specializing in autoimmune diseases, Memo Therapeutics, specialising in natural immunity, and Avidicure, specialising in cancer immunotherapy.


Copyright (c) 2024 CercleFinance.com. All rights reserved.